ArticleThe New England journal of medicine2015
Soluble Urokinase Receptor and Chronic Kidney Disease.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 240 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease
Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Who cites it
240 citing papers in PubMed, 4 syntheses or guidelines pooled it, 411 citations in OpenAlex.
- Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.The Journal of clinical investigation · 2022Pooled it
- Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.Communications biology · 2021Pooled it
- Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.Journal of immunology research · 2019Pooled it
- Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.BioMed research international · 2019Pooled it
- suPAR Identifies Treatment-Resistant Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes With Coronary Artery Disease: An Ancillary Analysis of BARI 2D.Diabetes care · 2026Trial
- Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.ESC heart failure · 2025Trial
- Inflammatory Markers and Measures of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes.Journal of the American Heart Association · 2025Trial
- Aggregate Clinical and Biomarker-Based Model Predicts Adverse Outcomes in Patients With Coronary Artery Disease.The American journal of cardiology · 2023Trial
- Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.Cardiovascular research · 2022Trial
- Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.Disease markers · 2019Trial
- Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.Journal of the American Society of Nephrology : JASN · 2018Trial
- Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study.Journal of cardiac failure · 2026Observational
- Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Plasma suPAR and domain-specific cognitive performance in virologically suppressed women with HIV.Journal of neurovirology · 2026Article
- Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.Journal of the American Heart Association · 2026Article
- Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study.Cardiovascular diabetology · 2026Article
- uPAR/suPAR Signaling and Organ Crosstalk in Cardiovascular-Kidney-Metabolic Syndrome.Circulation research · 2026Review
- Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-RiskmedRxiv : the preprint server for health sciences · 2026Article
- Selected tryptophan metabolites and inflammatory molecules in hemodialyzed patients.Pharmacological reports : PR · 2026Article
180 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundRelatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease.
methodsWe measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox regression after adjustment for demographic and clinical variables.
resultsA higher suPAR level at baseline was associated with a greater decline in the eGFR during follow-up; the annual change in the eGFR was -0.9 ml per minute per 1.73 m(2) among participants in the lowest quartile of suPAR levels as compared with -4.2 ml per minute per 1.73 m(2) among participants in the highest quartile (P<0.001). The 921 participants with a normal eGFR (≥ 90 ml per minute per 1.73 m(2)) at baseline had the largest suPAR-related decline in the eGFR. In 1335 participants with a baseline eGFR of at least 60 ml per minute per 1.73 m(2), the risk of progression to chronic kidney disease in the highest quartile of suPAR levels was 3.13 times as high (95% confidence interval, 2.11 to 4.65) as that in the lowest quartile.
conclusionsAn elevated level of suPAR was independently associated with incident chronic kidney disease and an accelerated decline in the eGFR in the groups studied. (Funded by the Abraham J. and Phyllis Katz Foundation and others.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.